Guidance System May Improve Light-Based Therapy for Mesothelioma

4142338_light2Using an infrared camera to guide the direction of a cancer-killing light may boost the effectiveness of photodynamic therapy for malignant pleural mesothelioma.

Pleural mesothelioma is an aggressive cancer that attacks the membrane surrounding the lungs. Photodynamic therapy (PDT), which uses light and a photosensitizing drug, can be used to kill residual cancer cells after debulking surgery. Uniform distribution of the light is key to the effectiveness of this mesothelioma therapy.

Now, a report presented at the 58th Annual Meeting of the American Association of Physicists in Medicine suggests that the process can be even more effective if an infrared camera is used to track the motion of the light source during treatment, ensuring even distribution.

Photodynamic Therapy for Mesothelioma

Photodynamic therapy for malignant mesothelioma is an emerging treatment that is primarily available only in larger centers. It is typically used in conjunction with lung-sparing pleurectomy/decortication surgery, during which the surgeon tries to remove as much of the pleural mesothelioma tumor as possible, along with other at-risk tissues.

The patient receives a dose of the photosensitizing drug a day prior to surgery. Cancer cells hold on to the photosensitizing drug longer than healthy cells, allowing for a highly targeted treatment approach.

After mesothelioma surgery, the surgeon directs a powerful cancer-killing laser light on the end of an endoscope into the thoracic cavity with the goal of destroyed any remaining cancer cells that may have been left behind.

Because PDT works differently than chemotherapy, radiation or surgery, it can be used along with these therapies as part of a multi-modality approach to mesothelioma treatment.

Tracking Cancer-Killing Light

According to Biophysicist Michele Kim and her colleagues at the University of Pennsylvania, PDT for mesothelioma is typically monitored by isotopic light detectors placed at specific locations inside the pleural cavity.

But a “real-time” tracking system that incorporates infrared camera technology may allow the user to be more precise with the light delivery, potentially making the treatment more effective and improving mesothelioma survival.

“It is possible to use the feedback system to deliver a more uniform dose of light throughout the pleural cavity,” reports Kim and her colleagues. “In a phantom study, the light distribution was improved by using real-time guidance compared to the distribution when using detectors without guidance.”

Ongoing PDT Mesothelioma Research

Penn’s previous studies on photodynamic therapy in combination with lung-sparing surgery have produced some of the best mesothelioma survival results to date.

A 2013 Penn study published in the Annals of Cardiothoracic Surgery showed a median survival of 31.7 months among 38 mesothelioma patients who underwent surgery and PDT. The results were especially notable since all of the patients had advanced disease. Patients in the study with the epithelioid type of mesothelioma survived even longer.

University of Pennsylvania researchers are in the midst of an NIH-funded clinical trial of PDT in pleural mesothelioma that began in 2014.

Source:

Kim, M, et al, “Update on a Real-Time Treatment Guidance System Using an IR Navigation System for Pleural PDT”, December 2016, Medical Physics, pp. 3672

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…